Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression is a research paper published in Cancer Cell (2005). On theSindex it has a DataRank of 1.0. It has been cited 810 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.0
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIGMS NIH HHS
Grant: R01 GM072007
NCI NIH HHS
Grant: UO1 CA111275-01
NCI NIH HHS
Grant: P50CA69568
NCI NIH HHS
Grant: 5P30 CA46592
NIA NIH HHS
Grant: R01AG21404
NIGMS NIH HHS
Grant: R01GM72007-01
MeSH Terms
Additional file 1 of ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Additional file 1 of ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Additional file 2 of ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Additional file 2 of ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Additional file 3 of ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Additional file 3 of ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Additional file 4 of ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Additional file 4 of ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Additional file 6 of Evaluating the transcriptional fidelity of cancer models
Additional file 6 of Evaluating the transcriptional fidelity of cancer models
Additional file 1 of AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Additional file 1 of AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Additional file 2 of AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Additional file 2 of AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Additional file 4 of AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Additional file 4 of AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Additional file 5 of AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Additional file 5 of AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
Additional file 1 of FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma
Additional file 1 of FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma